Compositions and methods for converting styrene to biodegradable alternatives

Provided are nucleic acids and vectors that collectively encode various gene products related to converting styrene to polyhydroxybutyrate (PHB). In some embodiments, the nucleic acids and vectors collectively encode a styrene monooxygenase polypeptide, a flavin reductase polypeptide, a styrene-oxide isomerase polypeptide, and a phenylacetaldehyde dehydrogenase polypeptide, an acetyl-CoA C-acetyltransferase polypeptide, a 3-ketoacyl-ACP reductase polypeptide, a class I poly(R)-hydroxyalkanoic acid synthase polypeptide, and optionally an influx porin polypeptide. Also provided are systems and methods for producing PHB from styrene, methods and systems for remediating polystyrene waste. In some embodiments, the systems are in vivo systems.

HIGH TEMPERATURE SEED GERMINATION

The present invention relates to a seed comprising in its genome a modified NXS gene and/or modified regulatory sequences thereof. The modified NXS gene and/or modified regulatory sequences thereof provides the seed with the capability to germinate at a high temperature as compared to a wild type seed not having the modified NXS gene. The modification to the gene and/or its regulatory sequences may lead to the expression of the NXS gene being substantially reduced or prevented. In addition to or alternatively, the seed can have a reduced level, reduced activity or complete absence of NXS protein. The modified NXS gene may for example comprise a premature stop codon and/or encode an NXS protein that comprises one or more amino acid substitutions. 120-. (canceled)21Lactuca sativa. A lettuce seed () comprising its genome a modified NXS gene , the wild type of which is identified in SEQ ID No. 1 , encoding the wherein the modified NXS gene encodes an NXS protein that comprises one or more amino acid substitutions.22. The lettuce seed as claimed in claim 21 , wherein a conserved residue of the encoded NXS protein of SEQ ID No. 2 is substituted.23. The lettuce seed as claimed in claim 22 , wherein the conserved residue is a proline residue which is substituted with a serine residue claim 22 , in particular proline at position 212 in the encoded protein of SEQ ID No. 2 is substituted with serine as a result of a C>T SNP at position 3518 of SEQ ID No. 1.24. The lettuce seed as claimed in claim 22 , wherein the conserved residue is a tryptophan residue which is substituted with any other amino acid resulting in a non-conservative amino acid change claim 22 , in particular tryptophan at position 175 of the encoded NXS protein of SEQ ID No. 2.2540-. (canceled) This application is a continuation-in-part application of International Patent Application Serial No. PCT/EP2015/071082 filed Sep. 15, 2015, which published as PCT Publication No. WO 2016/041952 on Mar. 24, 2016, which ...

Methods of using cyclooxygenase-prostacyclin synthase fusion gene

An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.

METHOD OF SELECTIVELY INHIBITING MPGES-1

A method of selectively inhibiting the overexpression of mPGES-1 in a subject in need thereof includes a step of administering an effective amount of a selective mPGES-1 inhibitor or a salt thereof to the subject. A method of treating a subject suffering from a disease associated with an overexpression of mPGES-1 and having a risk of cardiovascular event includes the step of administering an effective amount of a selective mPGES-1 inhibitor to the subject. 3. The method of claim 1 , wherein the subject is suffering from at least one of inflammatory disease claim 1 , neurological disease claim 1 , injury claim 1 , immune disease claim 1 , gastrointestinal disease claim 1 , or cancer.4. The method of claim 3 , wherein the subject is suffering from a cardiovascular disease.5. The method of claim 1 , wherein the subject is suffering from arthritis and is at risk of cardiovascular event.6. The method of claim 5 , wherein the cardiovascular event is selected from the group consisting of heart attack claim 5 , stroke claim 5 , myocardial infarction claim 5 , acute coronary syndrome claim 5 , arteriosclerosis claim 5 , thrombosis claim 5 , hypertension claim 5 , cardiovascular death claim 5 , and peripheral vascular disease.7. The method of claim 1 , further comprising steps of:obtaining a sample from the subject;testing the sample for the expression of mPGES-1;comparing the level of mPGES-1 expression with a reference to determine if the subject has an overexpression of mPGES-1; andoptionally determining if the subject is suffering from a cardiovascular disease or being at risk of a cardiovascular event.8. The method of claim 1 , wherein the administration of the selective mPGES-1 inhibitor suppresses the binding of nuclear factor κB to mPGES-1 promoter.9. The method of claim 1 , wherein the subject receives or received a long-term treatment of a non-steroidal anti-inflammatory drug.11. (canceled)12. (canceled)13. (canceled) The Sequence Listing file entitled “ ...

Methods for the treatment and diagnosis of bone mineral density related diseases

The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a hone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).

Hybrid protein that converts arachidonic acid into prostacyclin

A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G 2 (catalytic step 1), prostaglandin H 2 (catalytic step 2) and prostacyclin (PGI 2 ; catalytic step 3).

Method for inducing production of vascular endothelial growth factor

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin

Capsule protein and multimeric complex composition thereof, and pharmaceutical composition using same

There has been an idea to load a pharmaceutical agent in a barrel structure of a lipocalin-type prostaglandin D synthase, and to seal the pharmaceutical agent in the barrel structure by introducing a disulfide bond between H2-helix and E-F loop.However, in some cases the pharmaceutical agent is released through a gap in the vicinity of the open mouth of the barrel structure.The present capsule protein has substitution of alanine residue for a cysteine residue of the active center of the human lipocalin-type prostaglandin D synthetase. The protein further has substitution of barrier amino acid residue(s) for at least one amino acids of D strand. The barrier amino acids in the D-strand, located in the vicinity of the open mouth of its barrel structure suppresses the leak of the pharmaceutical agent.

METHOD FOR BIOCATALYTIC SYNTHESIS OF SUBSTITUTED OR UNSUBSTITUTED PHENYLACETIC ACIDS AND KETONES HAVING ENZYMES OF MICROBIAL STYRENE DEGRADATION

The present invention relates to a method for the biocatalytic synthesis of substituted and unsubstituted phenylacetic acids and ketones from styrenes and bicyclic aromatic hydrocarbons using enzymes of microbial styrene degradation in a whole-cell sensor, as well as a kit for the biocatalytic synthesis of substituted and unsubstituted phenylacetic acids and ketones containing a whole-cell catalyst and the use of the method, wherein the method comprises the following steps: 2. The method according to claim 1 , wherein the whole-cell catalyst comprises:i. a gene A which codes for the enzyme styrene monooxygenase and is under the functional control of a regulatable promoter, andii. a gene B which codes for the enzyme epoxide isomerase and is under the functional control of a regulatable promoter; ori. a gene A which codes for the enzyme styrene monooxygenase and is under the functional control of a regulatable promoter, andii. a gene D which codes for the enzyme styrene oxide reductase, in conjunction with a gene E which codes for the enzyme alcohol dehydrogenase, wherein the genes D and E are under the functional control of a regulatable promoter.3. The method according to claim 2 , the whole-cell catalyst further comprising:a gene C, which codes for the enzyme aldehyde dehydrogenase and is under the functional control of a regulatable promoter.4. The method according to claim 1 , wherein the whole-cell catalyst is selected from authentic bacterial cells claim 1 , recombinant bacterial cells claim 1 , or combination thereof.5Rhodococcus, Pseudomonas, Sphingobium, SphingopyxisCorynebacteriium.. The method according to wherein the whole-cell catalyst is authentic bacterial cells selected from claim 1 , and6Gordonia.. The method according to claim 1 , wherein the whole-cell catalyst is authentic bacterial cells selected from7. The method according to claim 4 , wherein the recombinant bacterial cells are negative mutations of authentic bacterial cells or insertion ...

Method for inducing production of vascular endothelial growth factor

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

HIGH TEMPERATURE SEED GERMINATION

The present invention relates to a seed comprising in its genome a modified NXS gene and/or modified regulatory sequences thereof. The modified NXS gene and/or modified regulatory sequences thereof provides the seed with the capability to germinate at a high temperature as compared to a wild type seed not having the modified NXS gene. The modification to the gene and/or its regulatory sequences may lead to the expression of the NXS gene being substantially reduced or prevented. In addition to or alternatively, the seed can have a reduced level, reduced activity or complete absence of NXS protein. The modified NXS gene may for example comprise a premature stop codon and/or encode an NXS protein that comprises one or more amino acid substitutions. 1. A seed comprising in its genome a modified NXS gene and/or modified regulatory sequences thereof.2. The seed of claim 1 , wherein the modified NXS gene and/or modified regulatory sequences thereof provides the seed with the capability to germinate at a high temperature as compared to a wild type seed not having the modified NXS gene.3. The seed as claimed in claim 1 , wherein the expression of the NXS gene is substantially reduced or prevented.4. The seed as claimed in claim 1 , wherein the seed has a reduced level claim 1 , reduced activity or complete absence of NXS protein claim 1 , as compared to a wild type seed not having the modified NXS gene.5. The seed as claimed in claim 1 , wherein the modified NXS gene comprises a premature stop codon and/or encodes an NXS protein that comprises one or more amino acid substitutions.6. The seed as claimed in claim 5 , wherein a conserved residue of the encoded NXS protein is substituted.7. The seed as claimed in claim 6 , wherein the conserved residue is in particular a proline residue which is substituted with a serine residue.8. A plant comprising in its genome a modified NXS gene and/or modified regulatory sequences thereof claim 2 , wherein the modified NXS gene is as ...

Matrix of rice husk silica for immobilizing enzyme and uses thereof

The present invention relates to a preparation method of a matrix of rice husk silica for immobilizing enzyme wherein a rice husk silica is modified with APTES((3-aminopropyl)triethoxysilane) and glutaraldehyde, a matrix of rice husk silica for immobilizing enzyme prepared by said method, a rice husk silica-enzyme complex wherein enzyme is immobilized onto said matrix of rice husk silica and a preparation method of valuable substances using said rice husk silica-enzyme complex. The rice husk silica having a nanoporous structure cannot only facilitate diffusion of substrate during enzyme reaction but also can be utilized as a path through which intermediates from the consecutive enzyme reactions can travel. Therefore, it can be effectively utilized in preparing valuable substances.

Drug composition for angiogenesis therapy

Drug compositions of angiogenesis therapy contain gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I 2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI 2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

Microbial Production of 2-Phenylethanol from Renewable Substrates

Described herein are engineered metabolic pathways in recombinant microorganism host cells which result in the production of 2-phenylethanol or 2-phenylacetic acid. Also described herein are methods of using the recombinant microorganisms for the production of 2-phenylethanol or 2-phenylacetic acid. 1. A recombinant organism comprising ,(i) at least one heterologous gene encoding an enzyme having phenylalanine ammonia lyase (PAL) activity,(ii) at least one heterologous gene encoding an enzyme having trans-cinnamic acid decarboxylase (CADC) activity,(iii) at least one heterologous gene encoding an enzyme having styrene monooxygenase (SMO) activity,(iv) at least one heterologous gene encoding an enzyme having styrene oxide isomerase (SOI) activity, and(v) at least one gene encoding an enzyme having 2-phenylacetaldehyde reductase (PAR) activity,wherein the recombinant microorganism is capable of producing 2-phenylethanol from a fermentable carbon substrate.2Escherichia coli.. The organism of claim 1 , wherein the organism is3E. coli.. The organism of claim 2 , wherein the organism is a phenylalanine overproducing strain of4Arabidopsis thaliana.. The organism of claim 1 , wherein the gene encoding a polypeptide having phenylalanine ammonia lyase activity is derived from5Saccharomyces cerevisiae.. The organism of claim 1 , wherein the gene encoding polypeptides having trans-cinnamic acid decarboxylase activity is derived from6Pseudomonas putida.. The organism of claim 1 , wherein the gene encoding a polypeptide having styrene monooxygenase activity is derived from7Pseudomonas putida.. The organism of claim 1 , wherein the gene encoding a polypeptide having styrene oxide isomerase activity is derived from8. A method of producing 2-phenylethanol comprising the steps of claim 1 ,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) contacting the recombinant organism of with a fermentable carbon substrate, and'}(ii) growing the recombinant organism for a time sufficient to ...

BIOPRODUCTION OF PHENETHYL ALCOHOL, ALDEHYDE, ACID, AMINE, AND RELATED COMPOUNDS

This invention relates to the bioproduction of substituted or unsubstituted phenylacetaldehyde, 2-phenylethanol, phenylacetic acid or phenylethylamine by subjecting a starting material comprising glucose, L-phenylalanine, substituted L-phenylalanine, styrene or substituted styrene to a plurality of enzyme catalyzed chemical transformations in a one-pot reaction system, using recombinant microbial cells overexpressing the enzymes. To produce phenylacetaldehyde from styrene, the cells are modified to overexpress styrene monooxygenase (SMO) and styrene oxide isomerase (SOI). To produce phenylacetic acid from styrene, SMO, SOI and aldehyde dehydrogenase are overexpressed. Alternatively, to produce 2-phenylethanol, SMO, SOI and aldehyde reductase or alcohol dehydrogenase are overexpressed, while to produce phenylethylamine, SMO, SOI and transaminase are overexpressed. 1. A method for bioproduction of substituted or unsubstituted phenylacetaldehyde , 2-phenylethanol , phenylacetic acid or phenylethylamine by one or more recombinant microbial cells genetically engineered to overexpress , relative to a wild type cell , at least one enzyme , which method comprises subjecting a starting material to a plurality of enzyme-catalyzed chemical transformations in a one-pot reaction system , wherein the starting material is selected from a group comprising glucose , L-phenylalanine or substituted L-phenylalanine , styrene or substituted styrene.2. The method of claim 1 , wherein the genetically engineered cells:i) overexpress styrene monooxygenase and styrene oxide isomerase for generating substituted or unsubstituted phenylacetaldehyde from styrene or substituted styrene; orii) overexpress styrene monooxygenase, styrene oxide isomerase and an aldehyde dehydrogenase for generating substituted or unsubstituted phenylacetic acid from styrene or substituted styrene; oriii) overexpress styrene monooxygenase, styrene oxide isomerase, an aldehyde reductase and/or an alcohol dehydrogenase ...

一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用

本发明提供了一种过表达Hpgds基因的重组脂肪干细胞、制备方法和及其应用，属于基因工程药物技术领域，所述重组脂肪干细胞通过将表达Hpgds基因的慢病毒载体感染脂肪干细胞获得。所述制备方法包括以下步骤：构建表达Hpgds基因的慢病毒载体；提取脂肪干细胞；将所述表达Hpgds基因的慢病毒载体感染脂肪干细胞获得重组脂肪干细胞；所述重组的脂肪干细胞在三维生物材料支架上进行增殖，能够安全、持久的表达免疫调节基因Hpgds，以加速糖尿病受损皮肤愈合，缩短愈合时间。

Functional Food including capsanthin having enhanced capacities of spontaneous locomotor activity and anti-fatigue activity

본 발명은 자발운동 촉진 및 항피로 활성이 있는 기능성 식품에 관한 것으로, 보다 상세하게는 화학식 1의 캅산틴을 포함함으로써, 섭취시에 에너지원으로부터 다량의 ATP를 생성하여 자발 운동을 촉진하고 강도 높은 운동 후에도 혈청중 젖산 및 암모니아 함량의 증가가 억제되어 항피로 활성을 가지는 기능성 식품에 관한 것이다. The present invention relates to a functional food having spontaneous exercise stimulation and antipyretic activity. More specifically, the present invention relates to a functional food having a spontaneous exercise promotion and an antipyretic activity. More specifically, The present invention relates to a functional food having anti-fatigue activity by suppressing an increase in lactate and ammonia content in serum after exercise.

Modulating beta-damascenone in plants

FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, in particular, to a transgenic tobacco plant cell having increased expression or activity of neoxanthin synthase compared to a wild type tobacco plant cell, to a plant, tobacco plant material and a tobacco composition comprising said cell. Also disclosed is a method for increasing the content of carotenoids in a tobacco plant, providing the increased expression or activity of neoxanthin synthase in a plant. Invention also relates to a method for producing a tobacco plant with a higher beta-damascenone content compared with a wild type tobacco plant, providing the increased expression or activity of neoxanthin synthase in a plant.EFFECT: invention allows efficiently producing a tobacco plant with a high content of carotenoids.9 cl, 7 dwg, 7 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 681 497 C2 (51) МПК C07K 14/415 (2006.01) C12N 15/82 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07K 14/415 (2018.08); C12N 15/8243 (2018.08); C12N 15/825 (2018.08); C12N 15/8271 (2018.08); C12N 9/90 (2018.08) (21)(22) Заявка: 2014121656, 30.10.2012 30.10.2012 Дата регистрации: (73) Патентообладатель(и): ФИЛИП МОРРИС ПРОДАКТС С.А. (CH) 06.03.2019 (56) Список документов, цитированных в отчете о поиске: US 2006265784 A1, 23.11.2006. EP 31.10.2011 EP 11187332.9; 25.01.2012 EP 12152508.3 (43) Дата публикации заявки: 10.12.2015 Бюл. № 34 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 02.06.2014 C 2 C 2 (45) Опубликовано: 06.03.2019 Бюл. № 7 1867723 A1, 19.12.2007. NORTH H.M et al., The Arabidopsis ABA-deficient mutant aba4 demonstrates that the major route for stressinduced ABA accumulation is via neoxanthin isomers, PLANT JOURNAL, 2007, vol. 50, no. 5. RU 2324737 C1, 20.05.2008. (86) Заявка PCT: EP 2012/071488 (30.10.2012) 2 6 8 1 4 9 7 2 6 8 1 4 9 7 Приоритет(ы): (30) Конвенционный приоритет: R U R U (24) Дата начала отсчета срока действия ...

High temperature seed is sprouted

本发明涉及在其基因组中包含经修饰的NXS基因和/或其经修饰的调控序列的种子。与不具有经修饰的NXS基因的野生型种子相比，经修饰的NXS基因和/或其经修饰的调控序列为该种子提供在高温下萌发的能力。对基因和/或其调控序列的修饰可能导致NXS基因的表达被显著降低或被阻止。除此之外或替代地，该种子可以具有降低的NXS蛋白水平、降低的NXS蛋白活性或完全不存在NXS蛋白。经修饰的NXS基因可以例如包含提前终止密码子和/或编码包含一个或多个氨基酸置换的NXS蛋白。

MODULATION OF BETA DAMASCENON IN PLANTS

1. Мутантная, не встречающаяся в природе или трансгенная растительная клетка, содержащая:(i) полинуклеотид, содержащий последовательность, кодирующую неоксантин-синтазу и имеющую по меньшей мере 60% идентичности последовательности с SEQ ID NO: 1 или SEQ ID NO: 6, или состоящий или фактически состоящий из нее;(ii) полипептид, кодируемый полинуклеотидом, изложенным в (i);(iii) полипептид, обладающий по меньшей мере 66% идентичности последовательности с SEQ ID NO: 2 или по меньшей мере 60% идентичности последовательности с SEQ ID NO: 7; или(iv) конструкт, вектор или вектор экспрессии, содержащий выделенный полинуклеотид, изложенный в (i),и причем экспрессия или активность неоксантин-синтазы изменена по сравнению с контрольным растением или растением дикого типа.2. Мутантное, не встречающееся в природе или трансгенное растение, содержащее растительную клетку по п. 1.3. Способ изменения содержания каротиноидов у растения, включающий следующие стадии:(a) изменение экспрессии или активности неоксантин-синтазы у растения, предпочтительно, причем неоксантин-синтаза охватывает:(i) полинуклеотид, содержащий последовательность, кодирующую неоксантин-синтазу и имеющую по меньшей мере 60% идентичности последовательности с SEQ ID NO: 1 или SEQ ID NO: 6, или состоящий или фактически состоящий из нее;(ii) полипептид, кодируемый полинуклеотидом, изложенным в (i); или(iii) полипептид, обладающий по меньшей мере 66% идентичности последовательности с SEQ ID NO: 2 или по меньшей мере 60% идентичности последовательности с SEQ ID NO: 7;(b) измерение содержания каротиноидов по меньшей мере в части мутантного, не встречающегося в природе или трансгенного растения, полученного на стадии (а); и(c) выя РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2014 121 656 A (51) МПК C07K 14/415 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2014121656/10, 30.10.2012 (71) Заявитель(и): ФИЛИП МОРРИС ПРОДАКТС С.А. (CH) Приоритет(ы): (30) Конвенционный ...

Modulating beta- damascenone in plants

Method of treatment for lung diseases using antisense oligonucleotides

A method of treating airway disease in a subject in need of such treatment is disclosed. The method comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the ariway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed.

Modulating beta-damascenone in plants

돌연변이, 비자연적으로 발생하는 또는 형질전환 식물 세포로서: (i) 네오크산틴 합성효소를 인코딩하며 SEQ ID NO:1 또는 SEQ ID No. 6과 적어도 60%의 서열 동일성을 가지는 서열을 포함하거나, 이로 구성되거나 또는 필수적으로 구성된 폴리뉴클레오티드; (ii) (i)의 폴리뉴클레오티드에 의하여 인코딩되는 폴리펩티드; (iii) SEQ ID NO:2와 적어도 66%의 서열 동일성을 가지거나 또는 SEQ ID No.7과 적어도 60%의 서열 동일성을 가지는 폴리펩티드; 또는 (iv) 분리된 (i)의 폴리뉴클레오티드를 포함하는 구성체, 벡터 또는 발현 벡터를 포함하며, 네오크산틴 합성효소의 발현 또는 활성이 대조군 또는 야생형 식물에 비하여 조절된 것인, 식물 세포.

Application of mPGES-2 as drug target for preventing and/or treating kidney diseases

本发明公开了mPGES‑2作为预防和/或治疗肾脏疾病的药物靶点的应用。本发明首次提出mPGES‑2是顺铂诱导的急性肾损伤的药物靶点。实验表明，mPGES‑2敲除可以显著降低由顺铂诱导的急性肾损伤小鼠血清中尿素氮和肌酐的水平，明显减轻由顺铂诱导的急性肾损伤小鼠肾组织形态损伤，同时显著改善了急性肾损伤小鼠肾脏中线粒体功能并减少了细胞凋亡。这些结果说明敲除mPGES‑2可改善顺铂诱导的急性肾损伤，表明mPGES‑2可以作为预防和/或治疗顺铂诱导的急性肾损伤的靶点，对今后此类疾病的药物开发及预防和/或治疗有非常重要的意义。

GENE ENCODING GENES OF CYANLASE (AOC), CISTATIN, BETA-1,3-GLUCANASEE OF TAUMATIN-LIKE PROTEIN ISOLATED FROM EUROPEAN CHESTNUT (CASTANEA SATIVA MILL.)

High temperature seed germination

The present invention relates to a seed comprising in its genome a modified NXS gene and/or modified regulatory sequences thereof. The modified NXS gene and/or modified regulatory sequences thereof provides the seed with the capability to germinate at a high temperature as compared to a wild type seed not having the modified NXS gene. The modification to the gene and/or its regulatory sequences may lead to the expression of the NXS gene being substantially reduced or prevented. In addition to or alternatively, the seed can have a reduced level, reduced activity or complete absence of NXS protein. The modified NXS gene may for example comprise a premature stop codon and/or encode an NXS protein that comprises one or more amino acid substitutions.

Low adenosine agent, composition, kit and method for treatment of airway disease

An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such treatment comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the airway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed.

Modulating beta-damascenone in plants

A mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a neoxanthin synthase and having at least 60% sequence identity to SEQ ID NO:1 or SEQ ID No. 6; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide having at least 66% sequence identity to SEQ ID NO:2 or at least 60% sequence identity to SEQ ID No. 7; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i), and wherein the expression or activity of the neoxanthin synthase is modulated as compared to a control or wild type plant.

Peripheral and neural inflammatory crosstalk

Disclosed are compositions and methods for the study and treatment of inflammatory disease, neurological disorders, bone disease, pain, and method s of making and using thereof.

Method for preparing prostaglandin E1 by using genetically engineered cyclooxygenase-1 and genetically engineered prostaglandin E synthetase-1

本发明公开了一种利用基因工程环氧合酶‑1和基因工程前列腺素E合成酶‑1制备前列腺素E1的方法，属于生物工程领域。该方法通过原核表达的手段表达出前列腺素E1合成所需要的相关酶，即环氧合酶‑1(COX‑1)和前列腺素E合成酶‑1(mPGES‑1)，利用酶与底物反应，进而合成出前列腺素E1。通过此法可以大量表达前列腺素合成酶并且合成出前列腺素E1，能够避免工业生产中活体上取下的组织酶容易污染的问题。同时原核表达出来的酶种类比较单一，表达的酶的浓度也比较高，而且大肠杆菌系统有机物杂质较少，酶促反应后的产物杂质相对较少，有利于前列腺素E1的纯化和利用，为人工合成前列腺素E1开辟了一条新的路径。

Vectors, compositions and methods for treating a vascular disorder

The present invention discloses vectors comprising a cyclooxygenase sequence, a prostaglandin synthase sequence or both. The invention further discloses methods of making such vectors, and compositions comprising such vectors. Methods for treating a patient afflicted with a vascular disorder by use of said vectors and compositions are also disclosed.

Modulating beta-damascenone in plants

A mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a neoxanthin synthase and having at least 60% sequence identity to SEQ ID NO:1 or SEQ ID No. 6; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide having at least 66% sequence identity to SEQ ID NO:2 or at least 60% sequence identity to SEQ ID No. 7; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i), and wherein the expression or activity of the neoxanthin synthase is modulated as compared to a control or wild type plant.

Matrix of rice husk silica for immobilizing enzyme and uses thereof

The present invention relates to a method for manufacturing rice husk silica matrix for enzyme immobilization in which (3-aminopropyl) triethoxysilane (APTES) and glutaraldehyde are modified in rice husk silica, rice husk silica matrix for enzyme immobilization manufactured by the method, a rice hull silica-enzyme complex in which an enzyme is immobilized on the rice husk silica matrix, and a method for producing useful substances using a husk silica-enzyme complex. The rice husk silica having a nano-pore structure not only can promote diffusion of substrates in enzyme reaction but also can be utilized as a passage through which an intermediate of a continuous enzyme reaction is transferred. Therefore, the rice husk silica may be effectively used for production of useful substances.

Drug composition for angiogenesis therapy of limb ischemia

Peripheral and neural inflammatory crosstalk

Disclosed are compositions and methods for the study and treatment of inflammatory disease, neurological disorders, bone disease, pain, and methods of making and using thereof.

Hybrid protein that converts arachidonic acid into prostacyclin

A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G2 (catalytic step 1), prostaglandin H2 (catalytic step 2) and prostacyclin (PGI2; catalytic step 3).

CASTANEA SATIVA MILL. GENES CODIFYING FOR ALLENE OXIDE CYCLASE, CYSTATIN, β-1,3-GLUCANASE AND THAUMATIN-LIKE PROTEIN AND THEIR USE

This invention provides isolated and purified nucleotide sequences which are differentially expressed during chestnut infection with the pathogenic fungus Phytophthtora cinnamomi Rands. The isolated genes can be inserted into expression cassettes and cloned in an expression vector which can be used to transform a host cell by selected transformation methods. Transgenic plants can be regenerated from transformed plant cells by in vitro culture techniques. The nucleotide sequences disclosed in this invention encode proteins which are described as having an effective action in plant resistance to pathogenic fungi. When used in sense orientation they can delay or even prevent plant infection, bringing important advantages for chestnut, cork-oak or other woody tree species’ producers.

Peripheral and neural inflammatory crosstalk

Disclosed are compositions and methods for the study and treatment of inflammatory disease, neurological disorders, bone disease, pain, and methods of making and using thereof.

Method for biocatalytic synthesis of substituted or unsubstituted phenylacetic acids and ketones having enzymes of microbial styrene degradation

The invention relates to a method for biocatalytic synthesis of substituted and unsubstituted phenylacetic acids and ketones from styrenes and bicyclic aromatic hydrocarbons using enzymes of microbial styrene degradation in a whole-cell sensor, and a kit for biocatalytic synthesis of substituted and unsubstituted phenylacetic acids and ketones comprising a whole-cell catalyst and to the use of the method, wherein the method comprises the following steps: a) providing of at least one type of whole-cell catalyst, comprising genes which are provided for the enzymes of the styrene degradation coding and functionally under the control of a controllable promoter, in an aqueous component, b) activating of the whole-cell catalyst by an inductor and/or an activator leads to expression of the genes, c) contacting the activated whole-cell catalyst to a substrate, d) isolating the formed reaction products, which advantageously are not metabolized further by the whole-cell catalyst and advantageously accumulate in the aqueous component.

一种胃癌模型猪的构建方法及应用

本发明提供了一种表达人WNT1、COX‑2和/或mPGES的猪细胞和由该猪细胞通过体细胞克隆技术获得的胃癌模型猪及其构建方法和在生物医药领域的应用。其中，包括将编码人WNT1、COX‑2和/或mPGES的核苷酸序列插入猪安全港位点，获得表达SEQ ID NO：14所示的WNT1、SEQ ID NO：15所示的COX‑2和/或SEQ ID NO：16所示的mPGES的猪细胞和胃癌模型猪，所述的猪安全港位点选自猪ROSA26、AAVS1、H11或COL1A1安全港位点。本申请研究对象应用性好，猪细胞中目的基因的表达量高、基因编辑效率高。

Germinacion de semilla a alta temperatura.

La presente invención se relaciona a una semilla que comprende en su genoma un gen de NXS modificado y/o secuencias regulatorias modificadas del mismo. El gen de NXS modificado y/o secuencias regulatorias modificadas del mismo proporcionan la semilla con la capacidad para germinar en una temperatura alta comparada con una semilla del tipo silvestre que no tiene el gen de NXS modificado. La modificación del gen y/o sus secuencias regulatorias pueden llevar a la expresión del gen de NXS que es substancialmente reducida o evitada. Además o alternativamente, la semilla puede tener un nivel reducido, actividad reducida o ausencia completa de proteína NXS. El gen de NXS modificado puede por ejemplo comprender un codón de detención prematuro y/o codificar una proteína NXS que comprende una o más substituciones de aminoácido.

Modeling of mPGES-1 three-dimensional structures: applications in drug design and discovery

This invention relates to representations of prostaglandin synthase three-dimensional structures. Such representations are suitable for designing agents that modulate the activity of the enzyme by binding to the substrate binding domain.

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogenic platelets.

Transformant and method for producing carotenoid composition using same

The present invention provides a technique for synthesizing a carotenoid composition by a genetic recombination technique. A transformant in which a first promoter, an upstream gene of a carotenoid biosynthesis gene including a crtY and crtZ operably linked to the first promoter, a second promoter having higher promoter intensity than the first promoter, and a ZEP gene and a CCS gene operably linked to the second promoter have been introduced into a host cell.

Transformant and method for producing carotenoid composition using same

The present invention provides a technique for synthesizing a carotenoid composition by a genetic recombination technique. A transformant in which a first promoter, an upstream gene of a carotenoid biosynthesis gene including a crtY and crtZ operably linked to the first promoter, a second promoter having higher promoter intensity than the first promoter, and a ZEP gene and a CCS gene operably linked to the second promoter have been introduced into a host cell.

Plaquetas manipuladas para entrega alvejada de um agente terapêutico

PLAQUETAS MANIPULADAS PARA ENTREGA ALVEJADA DE UM AGENTE TERAPÊUTICO. A presente invenção fornece plaquetas manipuladas com receptores de plaquetas quiméricos (CPR) com uma especificidade-alvo desejada. Além disso, as plaquetas manipuladas podem compreender carga que pode ser liberada após a ativação da plaqueta. Além disso, as plaquetas podem ser geradas in vitro a partir de megacariócitos manipulados para gerar plaquetas não trombogênicas.

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

Verfahren zur biokatalytischen synthese von substituierten oder unsubstituierten phenylessigsäuren und ketonen mit enzymen des mikrobiellen styrolabbaus

Die vorliegende Erfindung betrifft ein Verfahren zur biokatalytischen Synthese von substituierten und unsubstituierten Phenylessigsäuren und Ketonen aus Styrolen und bicyclischen aromatischen Kohlenwasserstoffen unter Verwendung von Enzymen des mikrobiellen Styrolabbaus in einem Ganzzellkatalysator, sowie ein Kit für eine solche biokatalytische Synthese enthaltend einen Ganzzellkatalysator, und neue Bakterienstämme und deren Verwendung in einem solchen Verfahren, wobei das Verfahren folgende Schritte umfasst: • a) Bereitstellung von mindestens einem Typ an Ganzzellkatalysator, enthaltend Gene, die für die Enzyme des Styrolabbaus kodieren und die funktionell unter die Kontrolle eines regulierbaren Promotors gestellt sind, in einer wässrigen Komponente, • b) Aktivierung des Ganzzellkatalysators mit einem Induktor und/oder einem Aktivator, der zur Expression der Gene führt, • c) Kontaktieren des aktivierten Ganzzellkatalysators mit einem Substrat, • d) Isolierung der gebildeten Reaktionsprodukte, die vorteilhaft von dem Ganzzellkatalysator nicht weiter verstoffwechselt werden und sich vorteilhaft in der wässrigen Komponente anreichern.

Composition derived from mammalian umbilical cord and whartons jelly for use in therapeutic and regenerative applications

A solution for topical application to the skin for therapeutic and regenerative applications comprises about 0.05% by weight of annexin-1, about 0.76% by weight of galectin-1, about 0.23% by weight of protein S-100, about 0.003% by weight of timp-1, about 0.01% by weight of timp-2, about 0.01% by weight of ECM1, about 0.2% by weight of adiponectin, about 0.002% by weight of nephroblastoma overexpressed protein, about 0.0003% by weight of prostacyclin synthase, about 0.001% by weight of C-X-X motif chemokine, about 2% by weight of heparan sulphate, and about 0.01% by weight of apolipoprotein D.

骨塩密度関連の疾患の治療および診断の方法

Modeling of mPGES-1 three-dimensional structures: applications in drug design and discovery

This invention relates to representations of prostaglandin synthase three-dimensional structures. Such representations are suitable for designing agents that modulate the activity of the enzyme by binding to the substrate binding domain.

Modeling of mPGES-1 three-dimensional structures: applications in drug design and discovery

This invention relates to representations of prostaglandin synthase three-dimensional structures. Such representations are suitable for designing agents that modulate the activity of the enzyme by binding to the substrate binding domain.

Methods for the treatment and diagnosis of bone mineral density related diseases

Described herein are methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, described herein are methods of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of such a mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. Also described are compounds such as a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). Additional aspects describe an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

Engineered platelets for targeted delivery of a therapeutic agent

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated

Engineered platelets for targeted delivery of a therapeutic agent

The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogenic platelets.

转化体以及使用其的类胡萝卜素组合物的制造方法

本发明提供一种通过基因重组技术来合成类胡萝卜素组合物的技术。一种转化体，其在宿主细胞中导入有：第一启动子、及与所述第一启动子可操作地连接的包含crtY和crtZ的类胡萝卜素的生物合成基因的上游基因；以及启动子强度比所述第一启动子高的第二启动子、及与所述第二启动子可操作地连接的ZEP基因和CCS基因。

Ｄｄｓカプセル用タンパク質およびそれを用いた薬剤とその調整方法

【課題】リポカリンファミリーはバレル構造によってポケットを有しており、いわばコップのような形状をしている。ここに、難水溶性の薬剤を収納することができる。しかも、薬剤によっては、複数個の分子単位を収納することができる。しかしながら、バレル構造によって形成されたポケットは、常に開口しており、移送の途中で内在させた薬物がこぼれてしまうおそれがある。 【解決手段】リポカリンファミリーをＤＤＳ用のカプセルとして利用する際に、バレル構造で形成されたポケット中に薬物を収納した後、ポケットの開口をジスルフィド架橋（Ｓ−Ｓ結合）によって閉じることができるようにするものである。具体的には、リポカリン型プロスタグランジンＤ合成酵素の酵素活性を失活させ、Ｎ末端から３４番目と９２番目のトリプトファンをシステインに置き換えたことを特徴とするＤＤＳカプセル用タンパク質を提供する。 【選択図】図２

Methods of using cyclooxygenase-prostacyclin synthase fusion gene

An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.

GhAOC4基因敲除创造棉花雄性不育和保持两用系的方法

本发明属于作物分子育种领域，具体涉及GhAOC4基因敲除创造棉花雄性不育和保持两用系的方法。特征为，分离一种棉花雄性不育性状相关的基因片段SEQ ID NO:1和SEQ ID NO:2，和作为分子标记应用的sgRNA1‑guidRNA、sgRNA2‑guidRNA序列，通过与CRISPR/Cas9系统和分子检测后得到棉花雄性不育系。所述的基因通过转基因后的表达被扰乱后，引起常温下棉花雄性不育。通过遗传转化获得棉花基因编辑突变体，早期的花蕾喷施5×10 ‑4 mol/L的茉莉酸甲酯溶液，可恢复突变体的雄性不育表型，通过自交扩繁，得到包含突变体基因的具有雄性不育和保持特征的两用系材料。

Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases

The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).

骨塩密度関連の疾患の治療および診断の方法

【課題】骨塩密度関連の障害の治療及び診断の方法、更に、骨塩密度の増加を伴う疾患（例えば、ゴサール血液骨幹異形成症候群）を治療又は予防するための化合物の提供。 【解決手段】トロンボキサン合成酵素（ＴＢＸＡＳ）１遺伝子の突然変異を検出することを含む、対象における骨塩密度関連の疾患又は骨塩密度関連の疾患のリスクを診断又は予測する方法であり、前記方法が、前記対象から採取した核酸試料においてＴＢＸＡＳ１の突然変異を検出するステップを含む方法。更に、骨塩密度の減少を伴う疾患（例えば骨粗鬆症）を治療又は予防するための、ＴＢＸＡＳ１遺伝子発現阻害薬又はトロンボキサン阻害薬からなる群から選択される化合物。 【選択図】なし

骨塩密度関連の疾患の治療および診断の方法

本発明は、骨塩密度関連の障害の治療および診断の方法に関する。より詳細には、本発明は、ＴＢＸＡＳ１遺伝子の突然変異を検出することを含む、対象における骨塩密度関連の疾患または骨塩密度関連の疾患のリスクを診断または予測する方法であって、前記突然変異の存在が骨塩密度関連の疾患または骨塩密度関連の疾患のリスクの指標となる方法に関する。本発明は、さらに、骨塩密度の増加を伴う疾患（例えば、ゴサール血液骨幹異形成症候群）を治療または予防するための、トロンボキサン合成酵素（ＴＸＡＳ）をコードするポリヌクレオチド、ＴＸＡＳ、トロンボキサンＡ２またはその類似体からなる群において選択される化合物にも関する。本発明は、さらに、骨塩密度の減少を伴う疾患（例えば骨粗鬆症）を治療または予防するための、ＴＢＸＡＳ１遺伝子発現阻害薬またはトロンボキサン阻害薬からなる群から選択される化合物にも関する。

一种丙二烯氧化物合成酶、编码基因CsAOS及其应用

本发明属于茶叶加工技术领域，尤其涉及一种丙二烯氧化物合成酶、编码基因CsAOS及其应用。其中丙二烯氧化物合成酶基因CsAOS的核苷酸序列如SEQ ID NO.1所示；丙二烯氧化物合成酶基因CsAOS编码的蛋白的氨基酸序列如SEQ ID NO.2所示。本发明提供了一种来源于茶叶且与茶叶香气相关的丙二烯氧化物合成酶基因CsAOS，且丙二烯氧化物合成酶基因CsAOS在不同适制性红茶绿茶品种中的表达差异显著。本发明通过体外瞬时表达以及体外寡核苷酸反义抑制实验发现并证明了，CsAOS的表达能够显著影响茶叶中挥发性物质以及茉莉酸类物质的含量，为茶叶的加工处理以及培育优良茶树品种提供新的技术手段。

一种自发性肾阴虚Ptgds基因敲除大鼠模型的构建方法

本发明属于生物工程技术领域，涉及一种自发性肾阴虚Ptgds基因敲除大鼠模型的构建方法，包括以下步骤：1)设计靶序列Ptgds‑sgRNA1/2；2)纯化Cas9mRNA、Ptgds‑sgRNA1/2；3)利用CRISPR/Cas9系统，将Ptgds基因内的序列片段进行靶向敲除；4)将纯化的Cas9mRNA、Ptgds‑sgRNA1/2和Ptgds敲除基因注射到大鼠胚胎得到新生大鼠；5)鉴定选择出杂合子大鼠；6)进一步与野生大鼠进行多代繁殖得到Ptgds基因敲除大鼠模型。本发明具有基因修饰精确性高，靶向性特异、实验周期短的优点，开发出可靠且稳定的基因工程模型，为更年期综合征相关疾病的治疗作用奠定基础。

Methods for the treatment and diagnosis of bone mineral density related diseases

The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).

一种ptgis高表达的sw480细胞系的构建方法及其应用

本发明涉及PTGIS高表达的SW480细胞系的构建方法，PTGIS基因全长的获得，Lentivirus‑puro‑PTGIS慢病毒质粒的构建、包装病毒，病毒侵染SW480细胞，而后经过嘌呤霉素的筛选，扩增后获得PTGIS稳定过表达的SW480细胞系。PTGIS高表达的SW480细胞系在结直肠癌中的应用。有益效果为：提出PTGIS基因在结直肠癌发展进程中的促进作用，及其作为靶点在结直肠癌诊断、治疗及预后的中的作用，通过挖掘TCGA数据库，发现PTGIS基因在结直肠癌样本中显著低表达，但与病人的五年高生存率显著相关，利用PTGIS过表的细胞系发现，PTGIS能够显著促进结直肠癌的增值与迁移。

Production of enantiopure alcohols, amines and acids from alkenes by cascade biotransformation involving 1,2-methyl shift

Disclosed herein is a method for producing an enantiomerically pure or enantiomerically enriched 2(R)- or 2(S)-phenylalkanal or a derivative thereof from trans-1-phenylalkene oxide or a derivative thereof using one or more recombinant microbial cells genetically engineered to overexpress an isomerase enzyme, a cell-free extract comprising the isomerase enzyme, a medium comprising a purified isomerase enzyme or a medium comprising an immobilized isomerase enzyme, wherein the transformation of the trans-1-phenylalkene oxide or a derivative thereof to 2(R)- or 2(S)-phenylalkanal or a derivative thereof involves a 1,2-alkyl shift reaction.

カプセルタンパク質とその多量体組成物およびそれを用いた医薬組成物

バレル構造を有するリポカリン型プロスタグランジンＤ合成酵素に薬剤を収納し、αヘリックスＨ２とＥ－Ｆループ間にジスルフィド結合を導入して、薬剤を閉じ込めるアイデアはあったが、バレル構造の開口の隙間から薬剤が放出される場合があった。　ヒト型リポカリン型プロスタグランジンＤ合成酵素の活性中心のシステインがアラニンに置換され、βストランドＤの少なくとも１つのアミノ酸を障壁アミノ酸に置換されたことを特徴とするカプセルタンパク質は、バレル構造の開口を構成するβストランドＤに設けた障壁アミノ酸によって、収納した薬剤の放出が抑制される。

GhAOC4基因敲除创造棉花雄性不育和保持两用系的方法

本发明属于作物分子育种领域，具体涉及GhAOC4基因敲除创造棉花雄性不育和保持两用系的方法。特征为，分离一种棉花雄性不育性状相关的基因片段SEQ ID NO:1和SEQ ID NO:2，和作为分子标记应用的sgRNA1‑guidRNA、sgRNA2‑guidRNA序列，通过与CRISPR/Cas9系统和分子检测后得到棉花雄性不育系。所述的基因通过转基因后的表达被扰乱后，引起常温下棉花雄性不育。通过遗传转化获得棉花基因编辑突变体，早期的花蕾喷施5×10 ‑4 mol/L的茉莉酸甲酯溶液，可恢复突变体的雄性不育表型，通过自交扩繁，得到包含突变体基因的具有雄性不育和保持特征的两用系材料。

Method for Constructing Ptgds Gene Knockout Rat Model with Spontaneous Kidney Yin Deficiency

The present disclosure belongs to the technical field of bioengineering, and relates to a method for constructing a Ptgds gene knockout rat model with spontaneous kidney yin deficiency. The method includes the following steps: 1) designing target sequences Ptgds-sgRNA1/2; 2) purifying Cas9mRNA and the Ptgds-sgRNA1/2; 3) conducting targeted knockout on a sequence fragment in the Ptgds gene using a CRISPR/Cas9 system; 4) injecting the purified Cas9mRNA, the purified Ptgds-sgRNA1/2, and a Ptgds knockout gene into rat embryos to obtain neonatal rats; 5) conducting genetic identification to select heterozygous rats; and 6) conducting breeding on the heterozygous rats with wild-type rats for multiple generations to obtain the Ptgds gene knockout rat model. In the present disclosure, the method has a high accuracy of gene modification, a targeting specificity, and a short experimental period.

一种自发性肾阴虚Ptgds基因敲除大鼠模型的构建方法

本发明属于生物工程技术领域，涉及一种自发性肾阴虚Ptgds基因敲除大鼠模型的构建方法，包括以下步骤：1)设计靶序列Ptgds‑sgRNA1/2；2)纯化Cas9mRNA、Ptgds‑sgRNA1/2；3)利用CRISPR/Cas9系统，将Ptgds基因内的序列片段进行靶向敲除；4)将纯化的Cas9mRNA、Ptgds‑sgRNA1/2和Ptgds敲除基因注射到大鼠胚胎得到新生大鼠；5)鉴定选择出杂合子大鼠；6)进一步与野生大鼠进行多代繁殖得到Ptgds基因敲除大鼠模型。本发明具有基因修饰精确性高，靶向性特异、实验周期短的优点，开发出可靠且稳定的基因工程模型，为更年期综合征相关疾病的治疗作用奠定基础。

Production of enantiopure alcohols, amines and acids from alkenes by cascade biotransformation involving 1,2-methyl shift

Disclosed herein is a method for producing an enantiomerically pure or enantiomerically enriched 2(R)- or 2(S)-phenylalkanal or a derivative thereof from trans-1-phenylalkene oxide or a derivative thereof using one or more recombinant microbial cells genetically engineered to overexpress an isomerase enzyme, a cell-free extract comprising the isomerase enzyme, a medium comprising a purified isomerase enzyme or a medium comprising an immobilized isomerase enzyme, wherein the transformation of the trans-1-phenylalkene oxide or a derivative thereof to 2(R)- or 2(S)-phenylalkanal or a derivative thereof involves a 1,2-alkyl shift reaction.

Capsule protein and multimeric complex composition thereof, and pharmaceutical composition using same

There has been an idea to load a pharmaceutical agent in a barrel structure of a lipocalin-type prostaglandin D synthase, and to seal the pharmaceutical agent in the barrel structure by introducing a disulfide bond between H2-helix and E-F loop.However, in some cases the pharmaceutical agent is released through a gap in the vicinity of the open mouth of the barrel structure.The present capsule protein has substitution of alanine residue for a cysteine residue of the active center of the human lipocalin-type prostaglandin D synthetase. The protein further has substitution of barrier amino acid residue(s) for at least one amino acids of D strand. The barrier amino acids in the D-strand, located in the vicinity of the open mouth of its barrel structure suppresses the leak of the pharmaceutical agent.

[UNK]

Capsule protein and multimeric complex composition thereof, and pharmaceutical composition using same

루테인 및 베타카로틴 함량이 높은 고추 판별용 마커

본 발명은, 루테인 및 베타카로틴 함량이 높은 고추 판별용 마커에 관한 것으로, 루테인 및 베타카로틴 함량이 높은 고추를 조기에 선발할 수 있는 마커를 개발하여 국내외의 육종회사에서 기능성 물질인 루테인 및 베타카로틴 함량이 높은 고추의 선발에 유용하게 이용할 수 있다.

Methods of using cyclooxygenase-prostacyclin synthase fusion gene

An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.

Hybrid protein that converts arachidonic acid into prostacyclin

A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G 2 (catalytic step 1), prostaglandin H 2 (catalytic step 2) and prostacyclin (PGI 2 ; catalytic step 3).

Hybrid protein that converts arachidonic acid into prostacyclin

A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G2 (catalytic step 1), prostaglandin H2 (catalytic step 2) and prostacyclin (PGI2; catalytic step 3).

Hybrid protein that converts arachidonic acid into prostacyclin

A recombinant 130-kDa protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostacyclin synthase (PGIS), via a 10-20 amino acid residues of a transmembrane sequence. The engineered protein is expressed in cells, and adopts the functions of COX and PGIS, to continually convert arachidonic acid (AA) into prostaglandin G2 (catalytic step 1), prostaglandin H2 (catalytic step 2) and prostacyclin (PGI2; catalytic step 3).

血管新生療法用医薬組成物

【課題】治療遺伝子の長期発現を実現し、ヒトへの臨床応用を可能とする血管新生療法において必要とされる末梢動脈疾患の治療又は予防に有効な血管新生療法用医薬組成物を提供する。 【解決手段】 少なくとも血管内皮増殖因子（ＶＥＧＦ）を産生させる 作用を有する物質であるプロスタグランジンＩ ２ （ＰＧＩ ２ ）を合成する ｈＰＧＩＳをコードする ｈＰＧＩＳ遺伝子 を 導入したアデノ随伴ウイルス（ＡＡＶ）を有効成分として含有し、ｈＰＧＩＳ遺伝子よりコードされたｈＰＧＩＳより合成されるプロスタグランジンＩ ２ （ＰＧＩ ２ ）により血管内皮増殖因子（ＶＥＧＦ）を産生し、この血管内皮増殖因子（ＶＥＧＦ）により末梢動脈の血管新生作用を増強し、末梢動脈疾患の治療又は予防を行う。 【選択図】 図３

血管新生療法用医薬組成物

本発明は、末梢動脈疾患の治療又は予防に用いられて有用な血管新生療法用医薬組成物であって、血管拡張作用及び／又は血小板凝集抑制作用を有する物質であるプロスタグランジンＩ２（ＰＧＩ２）を生じさせるヒトプロスタサイクリン合成酵素（ｈＰＧＩＳ）遺伝子と含有し、さらには血管新生因子をコードする遺伝子を含有したアデノ随伴ウイルス（ＡＡＶ）を有する医薬組成物である。この医薬組成物を治療目的とする部位に投与することにより、ＡＡＶｔｙｐｅ１−ｈＰＧＩＳの骨格筋内への遺伝子導入が図れ、骨格筋細胞内に著明なヒトＰＧＩＳ遺伝子発現を起こさせ、この遺伝子発現を介して筋細胞から産生・分泌されたＰＧＩ２が、血管保護作用、血管新生誘導作用を起こし、血管の虚血を改善させる。

Drug composition for angiogenesis therapy

Drug compositions of angiogenesis therapy contain gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I 2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI 2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

血管新生療法用医薬組成物

　本発明は、末梢動脈疾患の治療又は予防に用いられて有用な血管新生療法用医薬組成物であって、血管拡張作用及び／又は血小板凝集抑制作用を有する物質であるプロスタグランジンＩ２（ＰＧＩ２）を生じさせるヒトプロスタサイクリン合成酵素（ｈＰＧＩＳ）遺伝子と含有し、さらには血管新生因子をコードする遺伝子を含有したアデノ随伴ウイルス（ＡＡＶ）を有する医薬組成物である。この医薬組成物を治療目的とする部位に投与することにより、ＡＡＶｔｙｐｅ１－ｈＰＧＩＳの骨格筋内への遺伝子導入が図れ、骨格筋細胞内に著明なヒトＰＧＩＳ遺伝子発現を起こさせ、この遺伝子発現を介して筋細胞から産生・分泌されたＰＧＩ２が、血管保護作用、血管新生誘導作用を起こし、血管の虚血を改善させる。

利用枸杞茉莉酸代谢途径重要酶基因提高植物抗逆性的方法

本发明涉及一种利用枸杞茉莉酸代谢途径重要酶基因提高植物抗逆性的方法。枸杞茉莉酸生物合成途径丙二烯氧化物合酶基因<i>LmAOS</i>、丙二烯氧化物环化酶基因<i>LmAOC</i>、和OPDA还原酶基因选自以下核苷酸序列之一：1)具有SEQ？ID？No.1/2/3序列所示的核苷酸序列；通过提取新鲜枸杞叶片总RNA，通过3ˊ？RACE技术克隆枸杞丙二烯氧化物合酶基因<i>LmAOS</i>、丙二烯氧化物环化酶基因<i>LmAOC</i>、和OPDA还原酶基因<i>LmOPR</i>，得到完整的编码基因序列分别为1533bp、744bp、1203bp。构建了双元植物表达载体pCAMBIA2300-<i>LmAOS</i>、pCAMBIA2300-<i>LmAOC</i><i>、</i>pCAMBIA2300-<i>LmOPR</i>，电击法将载体转入农杆菌C58细胞，用这种细胞转化拟南芥，得到转基因拟南芥，用于后续有关抗逆性等的研究。

Hybrid protein with cox and pges enzyme activities

A representative hybrid or engineered protein is constructed by linking together human cyclooxygenase (COX) isoform-2 (COX-2) and prostaglandin E 2 synthase (PGES) via a 10-20 amino acid residues of a transmembrane sequence. The single protein molecule is expressed in cells, and adopts the functions of COX and PGES, to continually convert arachidonic acid (AA) into prostaglandin G 2 (catalytic step 1), prostaglandin H 2 (catalytic step 2) and prostaglandin E 2 (PGE 2 ; catalytic step 3). The COX-2-10aa-mPGES hybrid protein also converts dihomo-γ- linolenic acid (DGLA) into PGE 1 .

一种在酿酒酵母导入外源通路用于生产茉莉酸及衍生物的方法

本发明公开了一种在酿酒酵母导入外源通路用于生产茉莉酸及衍生物的方法，属于微生物技术领域。本发明提供了一株生产茉莉酸类化合物的酿酒酵母，以生物安全性高的酿酒酵母为底盘，导入高等植物中茉莉酸类物质的合成途径，首次实现了植物激素茉莉酸及其衍生物的异源从头合成，茉莉酸产量达到11.1mg/L；且该重组酵母菌株遗传背景清晰，便于基因操作，为后续通过基因改造实现茉莉酸类物质的高产奠定重要的基础。

转化体以及使用其的类胡萝卜素组合物的制造方法

本发明提供一种通过基因重组技术来合成类胡萝卜素组合物的技术。一种转化体，其在宿主细胞中导入有：第一启动子、及与所述第一启动子可操作地连接的包含crtY和crtZ的类胡萝卜素的生物合成基因的上游基因；以及启动子强度比所述第一启动子高的第二启动子、及与所述第二启动子可操作地连接的ZEP基因和CCS基因。

一种ptgis高表达的sw480细胞系的构建方法及其应用

本发明涉及PTGIS高表达的SW480细胞系的构建方法，PTGIS基因全长的获得，Lentivirus‑puro‑PTGIS慢病毒质粒的构建、包装病毒，病毒侵染SW480细胞，而后经过嘌呤霉素的筛选，扩增后获得PTGIS稳定过表达的SW480细胞系。PTGIS高表达的SW480细胞系在结直肠癌中的应用。有益效果为：提出PTGIS基因在结直肠癌发展进程中的促进作用，及其作为靶点在结直肠癌诊断、治疗及预后的中的作用，通过挖掘TCGA数据库，发现PTGIS基因在结直肠癌样本中显著低表达，但与病人的五年高生存率显著相关，利用PTGIS过表的细胞系发现，PTGIS能够显著促进结直肠癌的增值与迁移。